SuzanneKafajaMD
Rheumatology • Los Angeles, CAAssociate Clinical Professor/ Director Scleroderma Clinical Trials
Dr. Kafaja is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 UCLA Medical Plz Ste 365c
Los Angeles, CA 90095Phone+1 310-825-2448Fax+1 310-206-8606
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Rheumatology, 2008 - 2010
Olive View/UCLA Medical CenterResidency, Internal Medicine, 2005 - 2007
David Geffen School of Medicine at UCLAClass of 2001
Certifications & Licensure
CA State Medical License 2006 - 2026- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Scleroderma Spirit Leadership Award The Scleroderma Foundation, 2018
Clinical Trials
- Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension Start of enrollment: 2017 Jan 01
- Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis Start of enrollment: 2021 Feb 05
- Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis Start of enrollment: 2020 Jun 11
Publications & Presentations
PubMed
- Autologous non-myeloablative hematopoietic stem cell transplantation for diffuse cutaneous systemic sclerosis: identifying disease risk factors for toxicity and long-t...George E Georges, Dinesh Khanna, Mark H Wener, Matthew G Mei, Maureen D Mayes
Arthritis & Rheumatology. 2024-12-03 - Racial variability in immune responses only partially explains differential systemic sclerosis disease severity.Kamini E Kuchinad, Ji Soo Kim, Adrianne Woods, Gwen Leatherman, Laura Gutierrez-Alamillo
Annals of the Rheumatic Diseases. 2024-10-21 - 8 citationsEfficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.Robert Spiera, Masataka Kuwana, Dinesh Khanna, Laura Hummers, Tracy M Frech
Arthritis & Rheumatology. 2023-09-01
Journal Articles
- The Scleroderma Patient-Centered Intervention Network Cohort: Baseline Clinical Features and Comparison with Other Large Scleroderma CohortsDaniel E Furst, Robert Spiera, Maureen D Mayes, Lorinda Chung, Suzanne Kafaja, Virginia Steen, Shervin Assassi, Monique Hinchcliff, Rheumatology
Committees
- Medical Advisor, Medical Advisory board of Scleroderma Foundation of California 2023 - Present
- Scientific Abstract Review Committee, National Scleroderma Foundation 2022 - Present
Research History
- Medical Director, UCLA Scleroderma Clinical TrialsSince completing my fellowship in rheumatology in 2010, I had in depth training in systemic sclerosis. Since then I have been the PI and co investigator of major clinical trials in this field . I currently direct the. Scleroderma Clinical Trials at UCLA.2022 - Present
Professional Memberships
- Member
- Clinical Member
Other Languages
- Arabic, French, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
